Correlation Between Collplant Biotechnologies and Keros Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Collplant Biotechnologies and Keros Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Collplant Biotechnologies and Keros Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Collplant Biotechnologies and Keros Therapeutics, you can compare the effects of market volatilities on Collplant Biotechnologies and Keros Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Collplant Biotechnologies with a short position of Keros Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Collplant Biotechnologies and Keros Therapeutics.

Diversification Opportunities for Collplant Biotechnologies and Keros Therapeutics

-0.65
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Collplant and Keros is -0.65. Overlapping area represents the amount of risk that can be diversified away by holding Collplant Biotechnologies and Keros Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Keros Therapeutics and Collplant Biotechnologies is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Collplant Biotechnologies are associated (or correlated) with Keros Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Keros Therapeutics has no effect on the direction of Collplant Biotechnologies i.e., Collplant Biotechnologies and Keros Therapeutics go up and down completely randomly.

Pair Corralation between Collplant Biotechnologies and Keros Therapeutics

Given the investment horizon of 90 days Collplant Biotechnologies is expected to under-perform the Keros Therapeutics. In addition to that, Collplant Biotechnologies is 1.15 times more volatile than Keros Therapeutics. It trades about -0.09 of its total potential returns per unit of risk. Keros Therapeutics is currently generating about 0.16 per unit of volatility. If you would invest  4,535  in Keros Therapeutics on August 30, 2024 and sell it today you would earn a total of  1,320  from holding Keros Therapeutics or generate 29.11% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Collplant Biotechnologies  vs.  Keros Therapeutics

 Performance 
       Timeline  
Collplant Biotechnologies 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Collplant Biotechnologies has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.
Keros Therapeutics 

Risk-Adjusted Performance

12 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Keros Therapeutics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Keros Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Collplant Biotechnologies and Keros Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Collplant Biotechnologies and Keros Therapeutics

The main advantage of trading using opposite Collplant Biotechnologies and Keros Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Collplant Biotechnologies position performs unexpectedly, Keros Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Keros Therapeutics will offset losses from the drop in Keros Therapeutics' long position.
The idea behind Collplant Biotechnologies and Keros Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Other Complementary Tools

FinTech Suite
Use AI to screen and filter profitable investment opportunities
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Technical Analysis
Check basic technical indicators and analysis based on most latest market data